DrugDashboards

Nisoldipine

Nisoldipine · NISOLDIPINE 17 mg/1 · Tablet, Film Coated, Extended Release · Oral · Prasco Laboratories

NDC 66993-0473-02 · 1 BOTTLE in 1 CARTON / 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE · NDA AUTHORIZED GENERIC · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price is up 22% over the past year, to $4.66 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$4.66per EAinvoice-surveyed acquisition cost · Nov 19, 2025
  • Part D plans paid (avg)$4.59per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$4.40per unitnegotiated price across 1,500 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$4.40per unit
middle half $3.46$5.33 · 1,500 plans · Apr 1, 2026
Est. net of rebates
≈ $4.40
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
27%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Nov 2013Nov 2025$4.66
65 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$139.77
#90 count
$419.31

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2023)

$17,704
55 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for nisoldipine (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA020356
TE code
AB
Approval date
Feb 2, 1995
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · TerminatedJul 24, 2015
    Shionogi Inc.Failed Dissolution Specifications

Manufacturers of Nisoldipine (Tablet, Film Coated, Extended Release)

LabelerStrengthFirst seenLast seen
Covis Pharma US, IncNISOLDIPINE 8.5 mg/1Jul 15, 2026Sep 2, 2026
Covis Pharma US, IncNISOLDIPINE 17 mg/1Jul 15, 2026Sep 2, 2026
Covis Pharma US, IncNISOLDIPINE 34 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.NISOLDIPINE 8.5 mg/1Aug 5, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.NISOLDIPINE 17 mg/1Aug 5, 2026Sep 2, 2026
Prasco LaboratoriesNISOLDIPINE 8.5 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesNISOLDIPINE 17 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesNISOLDIPINE 34 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Nisoldipine — NDC 66993-0473-02," retrieved September 3, 2026, https://drugdashboards.com/drug/66993047302.

Free to cite with attribution — see how the data is put together.